Hostname: page-component-5447f9dfdb-2r8x7 Total loading time: 0 Render date: 2025-07-30T15:48:16.313Z Has data issue: false hasContentIssue false
  • English
  • Français

Is it now time to prepare psychiatry for a psychedelic future?: commentary, Breen et al

Part of: BJPsych Features: Psilocybin Therapy

Published online by Cambridge University Press:  06 February 2025

Eugene G. Breen Open the ORCID record for Eugene G. Breen [Opens in a new window]  and
Faisal Al-Harbi
Eugene G. Breen*
Affiliation:
Associate Clinical Professor, Department of Adult Psychiatry, Mater Misericordiae University Hospital, University College Dublin, Ireland
Faisal Al-Harbi
Affiliation:
Psychiatric Registrar, Mater Misericordiae University Hospital, University College Dublin, Ireland
*
Correspondence: Eugene G. Breen. Email: ebreen@mater.ie
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Psychedelicdepressionsocialdeterminantrisk

Information

Type
Commentary
Information
The British Journal of Psychiatry , Volume 226 , Issue 5 , May 2025 , pp. 319 - 320
Check for updates
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Nutt, D, Crome, I, Young, AH. Is it now time to prepare psychiatry for a psychedelic future? Br J Psychiatry 2024; 225(2): 308–3.CrossRefGoogle ScholarPubMed
Bremler, R, Katati, N, Shergill, P, Erritzoe, D, Carhart-Harris, RL. Case analysis of long-term negative psychological responses to psychedelics. Nat Sci Rep 2023; 13: 15998.Google ScholarPubMed
Kupferschmidt, AE. In a setback for psychedelic therapy, FDA advisers vote against medical use of ecstasy. Science 5 Jun 2024.Google Scholar
Kozlov, M. Your brain on shrooms — how psilocybin resets neural networks. Nature 2024; 631: 721.CrossRefGoogle ScholarPubMed
Hsu, T-W, Chia-Kuang, T, Yu-Chen, K, Thomson, T, Carvalho, AF, Fu-Chi, Y, et al. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. Br Med J 2024; 386: e078607CrossRefGoogle ScholarPubMed
Reardon, S. FDA rejects ecstasy as a therapy: what's next for psychedelics? Nature [Epub ahead of print] 13 Aug 2024. Available from: https://doi.org/10.1038/d41586-024-02597-x.Google Scholar
Mahase, E. MDMA assisted therapy: three papers are retracted as FDA rejects PTSD application. Br Med J 2024; 386: q1798.CrossRefGoogle ScholarPubMed
Hayes, C. Matthew Perry's Death Reveals Hollywood's Ketamine ‘Wild West’. BBC News, 26 Aug 2024 (https://www.bbc.co.uk/news/articles/czrgp7pj4g2o).Google Scholar
Adam, D. Ketamine is in the spotlight thanks to Elon Musk — but is it the right treatment for depression? Nature 2024; 627: 712–3.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.